The United States Food and Drug Administration (US FDA) conducted an inspection at Auroactive Pharma's manufacturing facility in Andhra Pradesh from June 22 to 26, 2026. According to reports from CNBC TV18 and Business Standard, the facility is located at Sy Nos 231, 285 to 291, Sancham Village, Ranasthalam Mandal, Srikakulam District, 523 409, Andhra Pradesh. Auroactive Pharma is a wholly owned subsidiary of Aurobindo Pharma and specializes in manufacturing Active Pharmaceutical Ingredients (API) & Pharmaceutical Formulation Intermediates. The company has confirmed that the inspection has been completed and the observations will be addressed within the stipulated timeframe.
The inspection concluded with 2 observations and will be responded to within the stipulated timeframe, as reported by CNBC TV18 and Business Standard. Aurobindo Pharma has announced this development to the stock exchange, providing transparency about the regulatory inspection process. The company has assured that there is no impact on its financials or operations as a result of the inspection, emphasizing its dedication to maintaining high-quality manufacturing standards. The official announcement was made on Saturday, June 27, 2026, with the company reiterating its commitment to maintaining the highest quality manufacturing standards and keeping stock exchanges informed of any further developments related to the inspection.
Following the positive regulatory clearance announcement, Aurobindo Pharma's stock responded positively to the news. According to Business Standard, the counter advanced 1.15% to ₹1,572.85 on the BSE, reflecting investor confidence in the regulatory compliance outcome. This market movement demonstrates the positive market sentiment towards the company's ability to maintain regulatory standards across its subsidiary operations.
Despite the regulatory inspection, Aurobindo Pharma has demonstrated strong financial performance in recent quarters. As reported by Business Standard, the company reported a 2% rise in consolidated net profit to ₹921.26 crore on a 4.4% increase in net sales to ₹8,751.50 crore in Q4 FY26 over Q4 FY25. The company is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services, positioning it well for continued growth in the pharmaceutical sector.
